Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isothipendyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.63 |
| ▸ | BLM | P54132 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isothipendyl SCHEMBL2556455 | 0.99 | LMNA (0.64) | LMNAPMP22BLMNPSR1KMT2A | |
| Isothipendyl SCHEMBL6035570 | 0.84 | KMT2A (0.79) | LMNAPMP22BLMKMT2ATSHR | |
| Isothipendyl SCHEMBL19555662 | 0.83 | KMT2A (0.81) | LMNAPMP22BLMKMT2ATSHR | |
| Promethazine SCHEMBL5708253 | 0.81 | CHRM2 (0.61) | LMNAPMP22BLMNPSR1KMT2A | |
| Chlorpheniramine SCHEMBL4284232 | 0.80 | LMNA (0.98) | LMNAPMP22BLMNPSR1TSHR | |
| Chlorpheniramine SCHEMBL4284230 | 0.80 | LMNA (0.98) | LMNAPMP22BLMNPSR1TSHR | |
| Chlorpheniramine SCHEMBL4359260 | 0.80 | LMNA (1.00) | LMNAPMP22BLMNPSR1TSHR | |
| Chlorpheniramine SCHEMBL14973510 | 0.80 | LMNA (1.00) | LMNAPMP22BLMNPSR1TSHR | |
| Chlorpheniramine SCHEMBL33358 | 0.80 | LMNA (1.00) | LMNAPMP22BLMNPSR1TSHR | |
| Chlorpheniramine SCHEMBL33357 | 0.80 | LMNA (1.00) | LMNAPMP22BLMNPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023309-B2 | Enhanced delivery epinephrine compositions | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240156720-A1 | COMPOSITIONS FOR BLOOD STORAGE AND TRANSFUSIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2024-05-16 | — | — | US | disclosed |
| WO-2024100162-A1 | PROCESS FOR FORMING AN AQUEOUS DISPERSION OF COPOLYMERS, AN ADHESIVE COMPOSITION INCLUDING SUCH COPOLYMERS, A FILM OR AN ARTICLE COMPRISING THE SAME, AND A METHOD OF COATING A SUBSTRATE | WACKER CHEMIE AG (DE) | 2024-05-16 | — | — | WO | disclosed |
| US-20240148673-A1 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240050362-A1 | TRANSDERMAL DELIVERY FORMULATIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2024-02-15 | — | — | US | disclosed |
| US-20240033214-A1 | TRANSDERMAL DELIVERY FORMULATIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2024-02-01 | — | — | US | disclosed |
| US-20240016734-A1 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| EP-3582754-B1 | COMPOSITION AND METHODS FOR PREVENTING RADIATION INJURY AND PROMOTING TISSUE REGENERATION | XEQUEL BIO INC (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023245069-A2 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11813284-B2 | Topical compositions and methods of using the same | NOVAN, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-6159498-A | WATER-SOLUBLE DELIVERY DEVICE FOR APPLICATION TO MUCOSAL SURFACES | VIROTEX CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| US-6103266-A | FILM-FORMING GEL COMPRISING WATER INSOLUBLE ALKYL CELLULOSE OR HYDROXYALKYL CELLULOSE, PHARMACOLOGICALLY ACCEPTABLE SOLVENT, PHARMACEUTICAL | TOLMAR THERAPEUTICS, INC. | 2000-08-15 | — | — | US | disclosed |
| EP-0973497-A1 | PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES | VIROTEX CORPORATION (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1999055312-A2 | PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES | VIROTEX CORPORATION (US) | 1999-11-04 | — | — | WO | disclosed |
| US-5955097-A | WATER INSOLUBLE, FILM-FORMING GEL CONTAINING HYDROXYALKYL- OR ALKYL CELLULOSE, DRUG, AND SOLVENT | VIROTEX CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0930873-A1 | PHARMACEUTICAL GEL PREPARATION APPLICABLE TO MUCOSAL SURFACES AND BODY TISSUES | VIROTEX CORPORATION (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999032152-A2 | METHODS FOR DELIVERING PHARMACEUTICAL AGENTS TO MUCOSAL SURFACES | MDV TECHNOLOGIES, INC. (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5800832-A | MULTILAYER DEVICE FOR DRUG DELIVERY, ADHESIVES LAYER AND BACKINGS | VIROTEX CORPORATION (US) | 1998-09-01 | — | — | US | disclosed |
| WO-1998017252-A1 | PHARMACEUTICAL GEL PREPARATION APPLICABLE TO MUCOSAL SURFACES AND BODY TISSUES | VIROTEX CORPORATION (US) | 1998-04-30 | — | — | WO | disclosed |
| WO-1998017251-A1 | PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES | VIROTEX CORPORATION (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016734-A1 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | ADRB1, ADRA1B, ADRA2C | HRH1 509/4885LMNA 1212/4885PMP22 2899/4885 |
| US-20240148673-A1 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | ADRA1B, ADRB1, ADRA2C | HRH1 537/4885LMNA 1117/4885PMP22 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.